Changes in Beneficial Ownership · 4
Merck & Co., Inc.
MRKNYSEEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-08-12
- Issuer
- Merck & Co., Inc.
- Issuer CIK
- 0000310158
- Trading symbol
- MRK
Reporting owner 1
- Name
- Zachary Jennifer
- Reporting owner CIK
- 0001737231
- Relationship
- Officer
- Officer title
- EVP, General Counsel
- Address
- MERCK & CO., INC., 126 EAST LINCOLN AVENUE, RAHWAY, NJ, 07065
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-12 | M · Form 4 | 41,494 | A | 117.89 | 112,391.254 | D |
| Common Stock | 2026-08-12 | M · Form 4 | 13,433 | A | 84.71 | 125,824.254 | D |
| Common Stock | 2026-08-12 | S · Form 4 | 80,315 | D | 133.4557[F1] | 45,509.254 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 117.89 | 2026-08-12 | M · Form 4 | 41,494 | D | 0 | 2024-05-02[F2] | 2033-05-01 | Common Stock | 41,494 | 0 | D |
| Stock Option (Right to Buy) | 84.71 | 2026-08-12 | M · Form 4 | 13,433 | D | 0 | 2026-04-29[F3] | 2035-04-28 | Common Stock | 13,433 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.0300 to $133.5000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.↩ 1
- F2
- The options vested and became exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026.↩ 1
- F3
- The options vest and become exercisable in equal installments on 4/29/2026, 4/29/2027, and 4/29/2028.↩ 1
Signature 1
- Signed
- /s/ Kelly E. W. Grez as Attorney-in-Fact for Jennifer Zachary
- Date
- 2026-08-13
Company context
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world - and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.